conjugate
agarose conjugate
type
Type V-B
form
buffered aqueous suspension
extent of labeling
~15 mg per mL
matrix
4% beaded agarose
matrix activation
p-nitrophenyl chloroformate
matrix spacer
1 atom
capacity
~6 mg/mL binding capacity (yeast mannan)
storage temp.
2-8°C
Biochem/physiol Actions
刀豆素 A 无血型特异性,但对末端 α-D-甘露糖基和 α-D-葡糖基残基具有亲和力。需要 Ca2+ 和 Mn2+ 离子存在才能显示活性。刀豆素 A 在 pH 6.5 或更低的条件下解离为二聚体。pH 在 5.8 至 7.0 之间时,刀豆素 A 以四聚体形式存在;pH 高于 7.0 时,形成更高的聚合体。根据聚合程度不同,刀豆素 A 可能显示出具有促有丝分裂的活性。琥珀酰化可以生成一种能够在 pH 高于 5.6 时仍保持二聚体形式的活性二聚体。
Physical form
Suspension in 0.1 M acetate buffer, pH 6.0, containing 1 M NaCl, 1 mM each Mn2+, Mg2+, and Ca2+, and 0.02% thimerosal
Analysis Note
Where reported, agglutination activity is expressed in μg/ml and is determined from serial dilutions in phosphate buffered saline, pH 6.8, containing Ca2+ and Mn2+ of a 1 mg per mL solution. This activity is the lowest concentration to agglutinate a 2% suspension of human erythrocytes after 1 hr incubation at 25 °C.
Still not finding the right product?
Explore all of our products under 伴刀豆球蛋白A 来源于洋刀豆 (刀豆)
存储类别
12 - Non Combustible Liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Tamara Potikha et al.
Hepatology (Baltimore, Md.), 58(1), 192-204 (2013-02-21)
Chronic inflammation is strongly associated with an increased risk for hepatocellular carcinoma (HCC) development. The multidrug resistance 2 (Mdr2)-knockout (KO) mouse (adenosine triphosphate-binding cassette b4(-/-) ), a model of inflammation-mediated HCC, develops chronic cholestatic hepatitis at an early age and
Mariam Al-Shamsi et al.
BMC gastroenterology, 13, 6-6 (2013-01-15)
A novel in vitro system was employed to investigate liver tissue respiration (mitochondrial O2 consumption) in mice treated with concanavalin A (Con A). This study aimed to investigate hepatocyte bioenergetics in this well-studied hepatitis model. C57Bl/6 and C57Bl/6 IFN-γ-/- mice
Shouichi Higashi et al.
The Journal of biological chemistry, 288(13), 9066-9076 (2013-02-12)
Synthetic inhibitors of matrix metalloproteinases (MMPs), designed previously, as well as tissue inhibitors of metalloproteinases (TIMPs) lack enzyme selectivity, which has been a major obstacle for developing inhibitors into safe and effective MMP-targeted drugs. Here we designed a fusion protein